Overall, there is therapeutic potential in inhibiting the progression of pancreatic cancer by targeting CDKN2A mutations, but further research is essential to fully comprehend the effectiveness of these treatments and develop more precise and impactful therapeutic strategies [60,61]. This evidence concerns the gene CDKN2A and familial pancreatic carcinoma.